tradingkey.logo
tradingkey.logo
Search

Zentalis Pharmaceuticals Announces 400Mg Qd 52 Azenosertib Monotherapy As The Pivotal Study Dose In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

ReutersApr 9, 2026 12:42 PM
facebooktwitterlinkedin

- Zentalis Pharmaceuticals Inc ZNTL.O:

  • ZENTALIS PHARMACEUTICALS ANNOUNCES 400MG QD 5:2 AZENOSERTIB MONOTHERAPY AS THE PIVOTAL STUDY DOSE IN CYCLIN E1-POSITIVE PLATINUM-RESISTANT OVARIAN CANCER

  • ZENTALIS PHARMACEUTICALS INC - DENALI PART 2 TOPLINE READOUT EXPECTED BY YEAR-END 2026

  • ZENTALIS PHARMACEUTICALS INC - DENALI PART 2C COHORT ENROLLMENT PLANNED FOR Q2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI